links.lww.com/IBD/B358

(1)

Supplemental Table 4 – Separation of cirrhosis and no cirrhosis in the OGD group

Factor

No cirrhosis (N=62)

Cirrhosis

(N=10) p-value

GP2 IgA 1.5 [1.00,2.6] 3.8 [2.1,6.8] 0.001^b

GP2 IgG 3.4 [2.3,6.1] 9.4 [1.7,15.8] 0.077^b

ASCA IgA 17.3 [12.7,29.0] 36.7 [32.4,41.6] 0.003^b ASCA IgG 9.1 [4.8,16.7] 24.4 [16.0,38.5] 0.009^b

GP2 IgA > 15 0 (0.0) 0 (0.0)

GP2 IgG > 15 3 (4.8) 3 (30.0) 0.008^c

ASCA IgA > 20 23 (37.1) 9 (90.0) 0.002^c

ASCA IgG > 20 23 (37.1) 9 (90.0) 0.002^c

Num. Positive Markers <0.001^b

. 0 39 (62.9) 1 (10.0)

. 2 20 (32.3) 6 (60.0)

. 3 3 (4.8) 3 (30.0)

Values presented as Median [P25, P75] or N (column %).

p-values: b=Kruskal-Wallis test, c=Pearson's chi-square test.

(2)

Comparison of CD subjects in Predictive Cohort and Those with Complications at or before sample procurement

Factor

Complication at or before sample

(N=233) Predictive Cohort

(N=70) p-value

Female 118(50.6) 42(60.0) 0.17^c

Age at diagnosis 28.1±12.0 29.8±13.4 0.31^a

Early disease onset 205(88.0) 58(82.9) 0.27^c

Age at sample procurement 35.7±12.5 37.4±12.5 0.31^a

BMI* 23.5±5.4 24.1±5.7 0.44^a

Disease duration (months) 73.4[20.1,136.5] 56.4[9.9,142.1] 0.66^b Location (non-exclusive)

Upper GI-tract* 24(10.4) 7(10.1) 0.94^c

Jejunum, prox. Ileum* 31(13.4) 4(5.9) 0.089^c

Ileocaecal 68(29.2) 25(35.7) 0.30^c

Colon (w/o Caecum) 37(15.9) 6(8.6) 0.12^c

Ileum and Colon* 128(55.2) 38(54.3) 0.90^c

Rectum* 73(31.5) 23(32.9) 0.83^c

Ileum involvement 196(84.1) 63(90.0) 0.22^c

Montreal classification 0.98^c

. B1 54(23.2) 15(21.4)

. B1p 16(6.9) 5(7.1)

. B2 66(28.3) 20(28.6)

. B2p 13(5.6) 5(7.1)

. B3 60(25.8) 16(22.9)

. B3p 24(10.3) 9(12.9)

Medications at sample procurement*

Infliximab 1(0.43) 0(0.0) 0.99^d

Steroids 118(50.9) 32(45.7) 0.45^c

Immunosuppressant 138(59.5) 38(54.3) 0.44^c

Medications during follow-up*

Infliximab 5(2.2) 1(1.4) 0.99^d

Steroids 135(58.2) 37(52.9) 0.43^c

Immunosuppressant 158(68.1) 43(61.4) 0.30^c

Marker Levels

GP2 Isoform 1 IgA 5.3[2.0,14.0] 7.1[2.4,17.0] 0.28^b GP2 Isoform 1 IgG 6.6[4.1,13.0] 7.0[3.6,11.8] 0.94^b GP2 Isoform 4 IgA* 1.3[0.90,1.9] 0.95[0.90,1.4] 0.024^b GP2 Isoform 4 IgG* 2.8[1.6,8.7] 2.2[1.4,5.4] 0.41^b

ASCA IgA 9.1[2.9,51.0] 21.4[3.0,51.2] 0.63^b

ASCA IgG 17.5[5.0,52.4] 21.7[7.6,54.6] 0.35^b

Marker Positivity

GP2 Isoform 1 IgA ≥ 2.6 161(69.1) 52(74.3) 0.40^c

(3)

Comparison of CD subjects in Predictive Cohort and Those with Complications at or before sample procurement

Factor

Complication at or before sample

(N=233) Predictive Cohort

(N=70) p-value

GP2 Isoform 1 IgG ≥ 7.3 ^105(45.1) ^33(47.1) ^0.76^c GP2 Isoform 4 IgA ≥ 1.3* 122(52.6) 25(35.7) 0.013^c GP2 Isoform 4 IgG ≥ 1.7* 172(74.1) 47(67.1) 0.25^c

ASCA IgA ≥ 5.5 143(61.4) 41(58.6) 0.67^c

ASCA IgG ≥ 25.2 97(41.6) 33(47.1) 0.41^c

*Data not available for all subjects. Missing values: BMI = 9, Upper GI-tract = 4, Jejunum, prox. Ileum = 4, Ileum and Colon = 1, Rectum = 1, Medications = 1, Isoform 4 = 1.

Values presented as Mean ± SD, Median [P25, P75] or N (column %).

p-value: a=ANOVA, b=Kruskal-Wallis test, c=Pearson's chi-square test, d=Fisher's Exact test.

(4)

Use of Steroids at time of sample procurement and marker levels (Predictive Cohort)

Factor

No Steroids (N=30)

Steroids

(N=39) p-value GP2 Isoform 1 IgA 4.0[2.0,11.5] 1.9[0.90,8.8] 0.070^b GP2 Isoform 1 IgG 5.8[4.2,8.1] 4.1[2.4,7.7] 0.21^b GP2 Isoform 4 IgA* 1.05[0.90,1.3] 0.90[0.90,1.3] 0.29^b GP2 Isoform 4 IgG* 2.3[1.2,4.2] 1.7[1.1,4.2] 0.40^b

ASCA IgA 2.5[2.1,23.5] 3.0[2.0,5.1] 0.76^b

ASCA IgG 7.8[4.2,22.7] 5.4[2.8,14.3] 0.25^b

GP2 Isoform 1 IgA ≥ 2.6 20(66.7) 16(41.0) 0.035^c GP2 Isoform 1 IgG ≥ 7.3 9(30.0) 10(25.6) 0.69^c GP2 Isoform 4 IgA ≥ 1.3* 13(43.3) 10(26.3) 0.14^c GP2 Isoform 4 IgG ≥ 1.7* 16(53.3) 19(50.0) 0.78^c

ASCA IgA ≥ 5.5 11(36.7) 9(23.1) 0.22^c

ASCA IgG ≥ 25.2 6(20.0) 6(15.4) 0.62^c

p-values: b=Kruskal-Wallis test, c=Pearson's chi-square test.

*Isoform 4 missing for 1 patient

Use of Immunosuppressant at time of sample procurement and marker levels (Predictive Cohort)

Factor

No

Immunosuppressant

(N=24) Immunosuppressant

(N=45) p-value GP2 Isoform 1 IgA 4.0[1.6,10.4] 2.4[0.90,8.8] 0.39^b

GP2 Isoform 1 IgG 5.8[4.4,8.6] 4.2[2.4,7.0] 0.11^b

GP2 Isoform 4 IgA* 0.95[0.90,1.3] 0.90[0.90,1.5] 0.98^b GP2 Isoform 4 IgG* 2.3[1.2,3.4] 1.7[1.2,4.8] 0.71^b

ASCA IgA 2.4[2.1,22.9] 3.6[2.0,6.6] 0.75^b

ASCA IgG 9.0[4.5,21.6] 5.2[2.8,14.3] 0.18^b

GP2 Isoform 1 IgA ≥ 2.6 14(58.3) 22(48.9) 0.45^c

GP2 Isoform 1 IgG ≥ 7.3 8(33.3) 11(24.4) 0.43^c

GP2 Isoform 4 IgA ≥ 1.3* 9(37.5) 14(31.8) 0.64^c

GP2 Isoform 4 IgG ≥ 1.7* 13(54.2) 22(50.0) 0.74^c

ASCA IgA ≥ 5.5 7(29.2) 13(28.9) 0.98^c

ASCA IgG ≥ 25.2 4(16.7) 8(17.8) 0.91^c

p-values: b=Kruskal-Wallis test, c=Pearson's chi-square test..

*Isoform 4 missing for 1 patient